A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

History of type 1 diabetes mellitus or a history of ketoacidosis

History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrine disorders, drug - or chemical-induced, and post-organ transplant)

History of nephrotic range proteinuria with hypoalbuminemia and edema

History of rapidly progressive glomerulonephritis, lupus nephritis, renal or systemic vasculitis, renal artery stenosis with renovascular hypertension, or ischemic nephropathy

History of familial renal glucosuria

History of renal dialysis or renal transplant or renal disease requiring treatment with any immunosuppressive agent

A known hypersensitivity or intolerance to any (sodium-glucose co-transporter 2) SGLT2 inhibitor

On a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable

Has undergone bariatric surgery within the past 12 months

Has been treated with rosiglitazone or other SGLT2 inhibitors within 12 weeks of study participation

Has active, obstructive uropathy or indwelling urinary catheter

History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation

A history of malignancy ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer

Known history of Human Immunodeficiency Virus (HIV)

Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells or any other clinically significant hematological disorder (such as aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or active symptomatic gallbladder disease

Has any clinically significant malabsorption condition

If taking thyroid replacement therapy, has not been on a stable dose for at least 6 weeks prior to study participation

Has been previously randomized in a study with ertugliflozin

Has participated in other studies involving an investigational drug within 30 days prior or during study participation

Has undergone a surgical procedure within 6 weeks prior to or during study participation

Has a positive urine pregnancy test

Is pregnant or breast-feeding, or is planning to conceive during the trial, including 14 days following the last dose of study medication

Planning to undergo hormonal therapy in preparation to donate eggs during the trial, including 14 days following the last dose of study medication

Excessive consumption of alcoholic beverages or binge drinking

Has donated blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial

What this study is about